FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 80 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Final DFS Analysis Demonstrates that Adjuvant Osimertinib Improves DFS in Patients... February 13, 2023 German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... February 18, 2020 Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas March 12, 2024 First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... July 21, 2023 Load more HOT NEWS Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic Preliminary Evidence of Efficacy of an Upfront ICI-based Therapeutic Strategy in... EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin
